Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced on November 1, 2022, the grant of non-qualified stock options for 350,025 shares to four newly hired employees. This grant is part of their 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $25.60 per share, equal to the stock's closing price on the grant date, and will vest over four years. Zentalis focuses on developing small molecule cancer therapeutics, with various oncology candidates in their pipeline.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a collaboration with Pfizer to initiate a Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in treating BRAF V600E-mutated colorectal cancer. This study aims to assess the combination of ZN-c3 with encorafenib and cetuximab, part of the BEACON regimen. With 21% of metastatic colorectal cancer patients harboring BRAF mutations, this collaboration addresses a significant unmet medical need. Patient enrollment is anticipated to start in Q1 2023, offering hope for improved treatment options in this aggressive cancer type.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Mark Lackner as Chief Translational Officer and Head of Biomarker Strategy. Dr. Lackner, a seasoned expert in oncology and biomarker development, brings over 20 years of experience from IDEAYA Biosciences and Genentech. This strategic hire aims to enhance Zentalis' clinical strategy and biomarker capabilities, particularly for the ongoing ZN-c3 biomarker trial. CEO Dr. Kimberly Blackwell emphasized that strengthening the executive team is crucial for advancing the company’s oncology pipeline, which includes promising candidates such as ZN-c3, ZN-d5, and ZN-c5.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the granting of equity awards to Dr. Carrie Brownstein, the new Chief Medical Officer, on October 3, 2022. The awards include non-qualified stock options to purchase 300,000 shares, 100,000 performance-based options, and 100,000 restricted stock units. The stock options have an exercise price of $22.21 per share, aligning with the closing price on the grant date. The grants were made under the 2022 Employment Inducement Incentive Award Plan, aiming to attract qualified personnel to Zentalis.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced the promotion of co-founder Kevin Bunker, Ph.D., to Chief Scientific Officer. In this role, he will lead R&D efforts in San Diego, focusing on advancing the preclinical pipeline and refining the Integrated Discovery Engine. Dr. Bunker, previously COO, has contributed significantly to the company's achievements, including developing leading oncology drug candidates like ZN-c3 and ZN-d5. The company's mission is to improve patient outcomes through innovative small molecule therapeutics targeting cancer pathways.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Carrie Brownstein as Chief Medical Officer, effective October 3, 2022. Bringing over 20 years of experience in oncology and hematology, Dr. Brownstein previously served as CMO of Cellectis and held key roles at Celgene, contributing to the approval of several novel products. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with lead programs ZN-c3 and ZN-d5. Dr. Brownstein aims to leverage her expertise to enhance clinical advancement at Zentalis.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the appointment of Dr. Jan Skvarka to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. Dr. Skvarka has a proven track record of leading clinical-stage companies and has successfully transformed Trillium Therapeutics, resulting in a significant acquisition by Pfizer. His expertise is expected to guide Zentalis as it develops its lead candidates, ZN-c3 and ZN-d5, which target various cancers. Zentalis aims to advance its pipeline of innovative cancer therapeutics amidst ongoing industry challenges.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on September 1, 2022, the grant of 125,000 non-qualified stock options to a new employee under the 2022 Employment Inducement Incentive Award Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $27.86, equivalent to the closing price on the grant date. The options will vest over four years. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with a pipeline that includes potential best-in-class candidates.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Kimberly Blackwell will participate in investor conferences. The 2022 Wells Fargo Healthcare Conference is set for September 7, 2022, at 2:35 p.m. ET in Boston, followed by the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:35 a.m. ET in New York City. Webcasts will be available on Zentalis' website.
As a clinical-stage biopharmaceutical firm, Zentalis focuses on small molecule therapies for cancer, with a diverse pipeline that includes potent candidates for various malignancies.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced key corporate developments and financial results for Q2 2022. The company appointed Dr. Kimberly Blackwell as CEO and Dave Johnson as Chairman, enhancing its leadership team. A $25 million equity investment from Pfizer aims to advance ZN-c3's clinical development. Zentalis raised approximately $200.2 million from a recent share offering, extending its cash runway into 2025. As of June 30, 2022, cash and marketable securities totaled $455.2 million, with R&D expenses slightly down to $43.8 million, while general administrative expenses rose to $19.6 million due to increased stock-based compensation.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
